ABSTRACT-We examined the effects of 1-methyl-4-phenylpyridinium ion (MPP+) on the release of DA in rat striatum by the in vivo microdialysis technique. For this study, we made a suitable micro dialysis probe from a 22-G needle, microliter pipette tip, silica tube and polyethylene tube. Such a re pairable microdialysis probe can be easily made from readily available and inexpensive materials. DA release, as determined by the 3-methoxytyramine level, was dose-dependently increased by MPP+ (1-10 mM). Only the presence of a 1 mM concentration of MPP+ in the dialysate significantly decreased the level of the DA metabolite DOPAC, while administration of higher MPP+ concentrations resulted in no significant change.
Parkinsonism is induced in various species by the systemic administration of the neurotoxin 1-methyl-4 phenyl-1,2,3,6-tetrahydropyridine (MPTP), which selec tively destroys the nigrostriatal dopamine (DA) neurons (1, 2) . Many studies indicated that the actual neuro toxin is a metabolite of MPTP, 1-methyl-4-phenyl pyridinium ion (MPP+), which is formed in a reaction catalyzed mainly by the B-form of monoamine oxidase (MAO-B, EC 1.4.3.4) in the brain (3 5) . In addition to the finding that MPP+ is produced by MAO-B catalysis, both MPTP and MPP+ were found to dose dependently inhibit rat striatal and forebrain MAO activity (5) . This enzyme has a key role in the induction of parkinsonism in humans after administration of MPTP because of the different localizations of MAO-A and MAO-B activity in various human brain areas as compared to rodent species (6) . The MAO inhibitory action may explain the decrease in the concentrations of the DA metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) without concurrent changes in DA levels in the striatum after MPTP administration to rats (7) . De termination of the 3-methoxytyramine (3-MT) level in an in vivo experiment is very important because 3-MT is an indicator of the amount of DA released into the synaptic cleft (8) . In this paper, we investigated the effect of MPP+ on the extracellular DA and its metabolites after perfusion of MPP+ into rat striatum.
Male Sprague-Dawley rats (350 to 450 g) were anes thetized with chloral hydrate (400 mg/kg, i.p.) and pre pared for intracranial microdialysis brain perfusion. The microdialysis probe (Fig. 1 ) was made from a 22-G nee dle and microliter pipette tip. The plastic hub of the needle and the point of the microliter pipette tip were removed, and its stainless steel tube was cut to an appropriate length. This tube and a fused slica tube (470-gum o.d. X 350-,um i.d.) were glued in place with epoxy resin. The flexible fused silica tubes (150-,um o.d. X 75-,um i.d., EICOM) were supported by a metal tube. One of the open ends of a tubular dialysate mem brane (220-,um o.d., 10-,um wall width., 50,000 MW cut-off; Cellulose hollow fiber) was sealed with the same resin. The tubular membrane was passed over the fused silica until the tip of the silica was 0.2 mm or less from the sealed end of the dialysis tubing. Finally, the joint between the membrane and the big silica tube was sealed with the resin under the dissecting microscope. A microdialysis probe (2 mm exposure) was stereotax ically placed in the striatum (stereotaxic coodinats: A: 1.0, R/L: 2.5, H: -7.0 mm from the dura matter) (9) . MPP+ was purchased from Research Biochemicals, Inc. (USA). The drugs were dissolved in the Ringer solution containing 147 mM NaCl, 2.3 mM CaC12, and 4 mM KCI, pH 6.0 for perfusion (1,u1/min) through the microdialysis probe into the striatum. After the sche duled washout with the Ringer solution, MPP+ (1 to 10 mM, 1 u 1/min) was infused for 15 min in order to evoke the release of'DA. The dialysate (1,ul/min) was collected every 15 min into 15,ul of ice-cold 0.1% Na2EDTA in 0.1 N HC1O4 and assayed immediately for DA, DOPAC, and 3-MT by a high performance liquid chromatograph with an electrochemical (HPLC-EC) procedure. Our microdialysis probe was tested in vitro to calculate the recovery of monoamines and metabo lites through the membrane under various conditions. The inlet side of the microdialysis probe was connected by a PE-20 (1.09-mm o.d.) polyethylene tube to a 1 ml syringe which was drive by a IP-2 microinfusion pump (BRC, Japan). The outlet side of the probe was con nected to the same tube and placed into a small collect ing tube. The probe was perfused with Ringer solution. The dialysis probe was then immersed into a Ringer solution. The recoveries of 10-7 M DA, DOPAC and 3-MT were about 20, 30 and 20%, respectively, at the flow rate of 1 ,ul/min. The dialysate samples were immediately injected for analysis into a HPLC-EC equipped with a WE-GC glassy carbon electrode (EICOM). The working electrode was set at a detector potential of 0.75 V. Monoamine and metabolites were separated on an Eicompak MA-SODS column (5 pm, 4.6 X 150 mm; EICOM). Each liter of mobile phase contained 1.5g heptane sulfonic acid sodium salt (Sigma Chemical Co., St. Louis, MO, USA), 0.1 g Na2EDTA, 3 ml triethylamine (Wako Pure Chemical Industries, Ltd., Japan), 125 ml acetonitrile (Wako) dissolved in H2O. The pH of the solution was adjusted to 2.8 with approximately 3 ml phosphoric acid (Wako) and filter ed through a millipore filter before the additional of acetonitrile. Flow rates between 0.7 and 1.5 ml/min allowed the samples to be assayed within 20 min. Re sults were reported as the mean and S.E.M. of the total output during a 120-min period. It has been reported that MPP+ produces a sustained massive DA over flow (10 -12) . DA levels especially in the brain regions (putamen, caudate nucleus and sub stantia nigra zona compacta) are high. The level of to tal DA in the brain dialysate increased dose-dependent ly following the administration of MPP+ (1 to 10 mM, Fig. 2) . Moreover, the level of 3-MT, which is an in dicator of the amount of DA released, greately in creased dose-dependently following the administration of MPP+. These data clearly indicated that the level of DA release was dose-dependently increased by MPP+. The present data also indicate a good correlation be tween the levels of released DA and increased 3-MT in the dialysate (8) . However, the level of the oxidized DA metabolite DOPAC in the dialysate significantly decreased following the administration of only 1 mM MPP+, which have resulted from the inhibition of pre synaptic MAO activity by the high concentration of MPP+. Kinemuchi et al. (13) suggest that MPP+ is an inhibitor of both MAO-A and MAO-B. The level of DOPAC was not changed when the MPP+ concentra tion was increased further, up to 10 mM. This finding of no further increase in the DOPAC levels by higher concentrations of MPP+ may be due to either the com plete inhibition of the MAO activity by 1 mM MPP+ or lack of the substrate DA, which may not be available for this enzyme after its release and/or both. Fig. 2 . Cumulative dose-response curve of MPP+ for the total efflux (during a 120-min period) of DA (EI), DOPAC (•) and 3 MT (/) from the rat striatum in vivo. The striatum of anesthe tized rats (chloral hydrate, 400 mg/kg, i.p.) was perfused with Ringer's solution (1 ,ul/min) through the probe for 3 hr prior to MPP+ administration. The pre-drug levels of DA, DOPAC and 3-MT were 0, 36.11 ± 4.69 and 0 pmols/15 min, respectively. Af ter a 60-min washout with Ringer's solution, MPP+ (1-10 mM) was infused into the striatum for 15 min. Brain dialysate was col lected every 15 min into ice-cold 0.1 % Na2EDTA in 0.1 N HC1O4 and immediately assayed for DA, DOPAC and 3-MT by an HPLC-EC procedure. Each value represents the mean and S.E.M. of five animals.
